PRNewswire (Mon, 17-Aug 8:01 AM ET)
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
PRNewswire (Fri, 14-Aug 7:01 AM ET)
PRNewswire (Wed, 12-Aug 8:01 AM ET)
PRNewswire (Mon, 10-Aug 8:01 AM ET)
PRNewswire (Mon, 3-Aug 8:00 AM ET)
PRNewswire (Tue, 14-Jul 8:00 AM ET)
PRNewswire (Wed, 8-Jul 8:00 AM ET)
PRNewswire (Tue, 16-Jun 8:00 AM ET)
ACXP Advances Groundbreaking Antibiotic Program with Lower R&D Spend and Solid Cash Position
Market Chameleon (Fri, 13-Mar 3:29 AM ET)
Acurx Unveils Promising Microbiome-Sparing Antibiotics: Class Effect May Revolutionize CDI Treatment
Market Chameleon (Tue, 28-Oct 5:09 AM ET)
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Acurx Pharmaceuticals trades on the NASDAQ stock market under the symbol ACXP.
As of August 27, 2026, ACXP stock price climbed to $1.46 with 84,906 million shares trading.
ACXP has a beta of -2.58, meaning it tends to be less sensitive to market movements. ACXP has a correlation of 0.04 to the broad based SPY ETF.
ACXP has a market cap of $6.27 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ACXP traded as high as $176.40 and as low as $1.31.
The top ETF exchange traded funds that ACXP belongs to (by Net Assets): VXF.
ACXP has underperformed the market in the last year with a price return of -70.0% while the SPY ETF gained +20.4%. ACXP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.6% and -1.4%, respectively, while the SPY returned +3.0% and -0.9%, respectively.
ACXP support price is $1.36 and resistance is $1.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACXP shares will trade within this expected range on the day.
